Use of a next generation maleimide in combination with THIOMAB (TM) antibody technology delivers a highly stable, potent and near homogeneous THIOMAB (TM) antibody-drug conjugate (TDC)
Author(s)
Type
Journal Article
Abstract
Herein we demonstrate that conjugation of a next generation maleimide (NGM) to engineered cysteines in a THIOMAB™ antibody delivers a THIOMAB™ antibody-drug conjugate (TDC) with a drug loading of ca. 2. This TDC is highly stable in blood serum conditions, selective and potent towards HER2 expressing cell lines and meets the current criteria for optimised antibody-drug conjugates (ADCs).
Date Issued
2017-05-10
Date Acceptance
2017-04-28
Citation
RSC Advances, 2017, 7 (40), pp.24828-24832
ISSN
2046-2069
Publisher
RSC
Start Page
24828
End Page
24832
Journal / Book Title
RSC Advances
Volume
7
Issue
40
Copyright Statement
© The Royal Society of Chemistry 2017. This is an open access article licensed under a
Creative Commons Attribution 3.0 Unported Licence (https://creativecommons.org/licenses/by/3.0/)
Creative Commons Attribution 3.0 Unported Licence (https://creativecommons.org/licenses/by/3.0/)
Sponsor
Ministry of Science, Innovation and Higher Education
Medical Research Council
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401525700035&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
Proof of Concept
Confidence in Concept
Subjects
Science & Technology
Physical Sciences
Chemistry, Multidisciplinary
Chemistry
SITE-SPECIFIC CONJUGATION
THERAPEUTIC INDEX
AMINO-ACIDS
STABILITY
EFFICACY
ADCS
PHARMACOKINETICS
ENABLES
PROTEIN
BIOCONJUGATION
Publication Status
Published